Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L. G., Shannon, K., Haanen, J. B. A. G., Stretch, J., Ch’ng, S., Nieweg, O. E., Mallo, H. A., Adriaansz, S., Kerkhoven, R. M., Cornelissen, S., Broeks, A., Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Peeper, D. S., Spillane, A. J., van Akkooi, A. C. J., Scolyer, R. A., Schumacher, T. N. M., Menzies, A. M., Long, G. V., Blank, C. U.
Published in Nature medicine (01.02.2021)
Published in Nature medicine (01.02.2021)
Get full text
Journal Article
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
Dimitriou, F., Namikawa, K., Reijers, I.L.M., Buchbinder, E.I., Soon, J.A., Zaremba, A., Teterycz, P., Mooradian, M.J., Armstrong, E., Nakamura, Y., Vitale, M.G., Tran, L.E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K.C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C.J., Zaman, F., Haydon, A., Carvajal, R.D., Hamid, O., Dummer, R., Hauschild, A., Carlino, M.S., Mandala, M., Robert, C., Lebbe, C., Guo, J., Johnson, D.B., Ascierto, P.A., Shoushtari, A.N., Sullivan, R.J., Cybulska-Stopa, B., Rutkowski, P., Zimmer, L., Sandhu, S., Blank, C.U., Lo, S.N., Menzies, A.M., Long, G.V.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
Owen, C.N., Bai, X., Quah, T., Lo, S.N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I.L.M., Thompson, N., Vanella, V., Gerard, C.L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C.U., Welsh, S.J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J.L., Ascierto, P.A., Zimmer, L., Johnson, D.B., Arance, A., Lorigan, P., Lebbé, C., Carlino, M.S., Sullivan, R.J., Long, G.V., Menzies, A.M.
Published in Annals of oncology (01.07.2021)
Published in Annals of oncology (01.07.2021)
Get full text
Journal Article
1329PComparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Versluis, J M, Reijers, I L M, Rozeman, E A, van Akkooi, A C J, van Houdt, W J, Bierman, C, van de Wiel, B A, Long, G V, Blank, C U
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1259PSwitch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma
Reijers, I L M, Rozeman, E A, Mallo, H, Uyterlinde, W, Adriaansz, S, Lijnsvelt, J, Wilgenhof, S, van Thienen, J V, Haanen, J B A G, Blank, C U
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1328PContinental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial
Reijers, I L M, Rozeman, E A, Menzies, A M, Versluis, J M, van de Wiel, B A, Sikorska, K, Eriksson, H, Shannon, K, Bierman, C, van Tinteren, H, Gonzalez, M, Spillane, A J, Saw, R P, Scolyer, R A, van Akkooi, A C J, Hansson, J, Long, G V, Blank, C U
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1313PD3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)
Blank, C U, Versluis, J M, Reijers, I L M, Sikorska, K, van Houdt, W J, van Thienen, J V, Adriaansz, S, Mallo, H A, van Tinteren, H, van de Wiel, B A, Grijpink-Ongering, L G, Bruining, A, Haanen, J B A G, van Akkooi, A C J, Schumacher, T N, Rozeman, E A
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma
Reijers, I.L.M., Rozeman, E.A., Mallo, H., Uyterlinde, W., Adriaansz, S., Lijnsvelt, J., Wilgenhof, S., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article